Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

From prostate cancer to breast cancer: In conversation with ...

Advancing the frontiers of cancer diagnostics: Post-ASCO wit...

Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.

Exploring the unconventional to provide hope: Dr Jason Willi...

Putting patients and their families first: Dr Corina Dutcus,...

Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, discusses the data Eisai presented at ASCO 2025.

Enhancing anti-tumour activity: A post-ASCO conversation wit...